drugset / Trial / NCT05940558
Safety and Efficacy of MBF-118 in Patients with Crohn Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on top of standard of care.
Timeline
- Start
- 2023-04-12
- Primary completion
- 2024-09-10
- Completion
- 2024-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBF-118 | Unknown | 100 mg | Oral |
| Subject | MBF-118 | Unknown | 200 mg | Oral |